Money: Scientists from Wroclaw are working on breakthrough drugs for dogs, horses and cats. They are being supported by experienced investors. The objective is clear: Bioceltix wants to become one of the first companies in the world to register it’s stem-cell-based biopharmaceutical with the European Medicines Agency (EMA).
– the market for veterinary biopharmaceuticals is still in its early stages of development. It was just 2 two years ago that the first biopharmaceutical drug in EMA history was registered. We’re looking to change the current state of the market, says Bioceltix CEO, Łukasz Bzdzion. Find out more about what Bioceltix has in store.